Tomatoes, lysophosphatidic acid, and the small intestine: New pieces in the puzzle of apolipoprotein mimetic peptides?

Journal of Lipid Research

Volumn 54, Issue 12, 2013, Pages 3223-3226

  Remaley, A T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4F PEPTIDE; 6F PEPTIDE; ABC TRANSPORTER A1; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN MIMETIC PEPTIDE; AUTOTAXIN; HIGH DENSITY LIPOPROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; DYSLIPIDEMIA; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPID OXIDATION; NONHUMAN; NOTE; PRIORITY JOURNAL; SMALL INTESTINE; STRUCTURE ACTIVITY RELATION; TOMATO;

ANIMALS; DIET; DYSLIPIDEMIAS; FEMALE; INTESTINE, SMALL; LYCOPERSICON ESCULENTUM; LYSOPHOSPHOLIPIDS; PEPTIDOMIMETICS;

EID: 84887938448     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E045054     Document Type: Note

References (23)

1. Navab, M., S. T. Reddy, B. J. Van Lenten, G. M. Buga, G. Hough, A. C. Wagner, and A. M. Fogelman. 2012. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler. Thromb. Vasc. Biol. 32:2553-2560.
2. Anantharamaiah, G. M., J. L. Jones, C. G. Brouillette, C. F. Schmidt, B. H. Chung, T. A. Hughes, A. S. Bhown, and J. P. Segrest. 1985. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 260:10248-10255. (Pubitemid 16246560)
3. Van Lenten, B. J., M. Navab, G. M. Anantharamaiah, G. M. Buga, S. T. Reddy, and A. M. Fogelman. 2008. Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. Curr. Opin. Investig. Drugs. 9:1157-1162.
4. Remaley, A. T., M. Amar, and D. Sviridov. 2008. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev. Cardiovasc. Ther. 6:1203-1215.
5. Sethi, A. A., M. Amar, R. D. Shamburek, and A. T. Remaley. 2007. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs. 8:201-212. (Pubitemid 46438455)
6. Sethi, A. A., J. A. Stonik, F. Thomas, S. J. Demosky, M. Amar, E. Neufeld, H. B. Brewer, W. S. Davidson, W. D'Souza, D. Sviridov, et al. 2008. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J. Biol. Chem. 283:32273-32282.
7. Vedhachalam, C., V. Narayanaswami, N. Neto, T. M. Forte, M. C. Phillips, S. Lund-Katz, and J. K. Bielicki. 2007. The C-terminal lipidbinding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry. 46:2583-2593. (Pubitemid 46417902)
8. Amar, M. J., W. D'Souza, S. Turner, S. Demosky, D. Sviridov, J. Stonik, J. Luchoomun, J. Voogt, M. Hellerstein, and A. T. Remaley. 2010. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J. Pharmacol. Exp. Ther. 334:634-641.
9. Bielicki, J. K., H. Zhang, Y. Cortez, Y. Zheng, V. Narayanaswami, A. Patel, J. Johansson, and S. Azhar. 2010. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J. Lipid Res. 51:1496-1503.
10. Van Lenten, B. J., A. C. Wagner, C. L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. 2008. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49:2302-2311.
11. Bloedon, L. T., R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. De Groot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader. 2008. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49:1344-1352.
12. Watson, C. E., N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S. T. Reddy, et al. 2011. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52:361-373.
13. Navab, M., S. T. Reddy, G. M. Anantharamaiah, S. Imaizumi, G. Hough, S. Hama, and A. M. Fogelman. 2011. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J. Lipid Res. 52:1200-1210.
14. Chattopadhyay, A., M. Navab, G. Hough, F. Gao, D. Meriwether, V. Grijalva, J. R. Springstead, M. N. Palgnachari, R. Namiri-Kalantari, F. Su, et al. 2013. A novel approach to oral apoA-I mimetic therapy. J. Lipid Res. 54:995-1010.
15. Datta, G., M. Chaddha, S. Hama, M. Navab, A. M. Fogelman, D. W. Garber, V. K. Mishra, R. M. Epand, R. F. Epand, S. Lund-Katz, et al. 2001. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42:1096-1104. (Pubitemid 32645791)
16. Schober, A., and W. Siess. 2012. Lysophosphatidic acid in atherosclerotic diseases. Br. J. Pharmacol. 167:465-482.
17. Mills, G. B., and W. H. Moolenaar. 2003. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer. 3:582-591. (Pubitemid 37328830)
18. Aoki, J., A. Inoue, and S. Okudaira. 2008. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta. 1781:513-518.
19. Zhao, Y., and V. Natarajan. 2013. Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling. Biochim. Biophys. Acta. 1831:86-92.
20. Dusaulcy, R., C. Rancoule, S. Gres, E. Wanecq, A. Colom, C. Guigne, L. A. Van Meeteren, W. H. Moolenaar, P. Valet, and J. S. Saulnier-Blache. 2011. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J. Lipid Res. 52:1247-1255.
21. Shen, X., W. Wang, L. Wang, C. Houde, W. Wu, M. Tudor, J. R. Thompson, C. M. Sisk, B. Hubbard, and J. Li. 2012. Identification of genes affecting apolipoprotein B secretion following siRNAmediated gene knockdown in primary human hepatocytes. Atherosclerosis. 222:154-157.
22. Zhou, Z., P. Subramanian, G. Sevilmis, B. Globke, O. Soehnlein, E. Karshovska, R. Megens, K. Heyll, J. Chun, J. S. Saulnier-Blache, et al. 2011. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 13:592-600.
23. Su, F., K. R. Kozak, S. Imaizumi, F. Gao, M. W. Amneus, V. Grijalva, C. Ng, A. Wagner, G. Hough, G. Farias-Eisner, et al. 2010. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc. Natl. Acad. Sci. USA. 107:19997-20002.